Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention

Acta Cytologica

Volumn 60, Issue 6, 2016, Pages 501-512

  Lorincz, Attila T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biomarkers; Cervical cancer; Cervical intraepithelial neoplasia; Classifier; Diagnostics; DNA methylation; Epigenetics; Human papillomavirus; Molecular signature; Score; Triage

Indexed keywords

BIOLOGICAL MARKER; DNA; VIRAL PROTEIN; VIRUS DNA;

CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CPG ISLAND; CYTOLOGY; DISEASE COURSE; DNA METHYLATION; DNA METHYLATION ASSAY; EMERGENCY HEALTH SERVICE; EPIGENETICS; FEMALE; GENE DOSAGE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN GENOME; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INDEL MUTATION; MOLECULAR DIAGNOSIS; NONHUMAN; OPEN READING FRAME; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SOMATIC MUTATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; GENETIC EPIGENESIS; GENETICS; METABOLISM; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

BIOMARKERS; DNA METHYLATION; DNA, VIRAL; EPIGENESIS, GENETIC; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84994071601     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000450595     Document Type: Review

References (57)

1. Lorincz AT: Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn 2014; 14: 293-305.
2. Robertson KD: DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610.
3. Rasool M, Malik A, Naseer MI, Manan A, Ansari SA, Begum I, Qazi MH, Pushparaj PN, Abuzenadah AM, Al-Qahtani MH, Kamal MA, Pushparaj PN, Gan SH: The role of epigenetics in personalized medicine: challenges and opportunities. BMC Med Genomics 2015: 8(suppl 1):S5.
4. Liu S, Wang J, Su Y: Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res 2013: 41: 6421-6429.
5. Illingworth RS, Bird AP: CpG islands-'a rough guide'. FEBS Let 2009; 583: 1713-1720.
6. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM: Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011; 21: 1028-1041.
7. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C, Clark SJ: Regional activation of the cancer genome by long-range epigenetic remodelling. Cancer Cell 2013; 23: 9-22.
8. Lorincz AT, Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A, Cuzick J, Sasieni P: HPV16 L1 and L2 DNA methylation predicts high grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 2013; 133: 637-644.
9. Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, Herrero R, Hildesheim A, Wacholder S, Scibior-Bentkowska D, Burk RD, Lorincz AT: Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013; 132: 1412-1422.
10. Louvanto K, Franco EL, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F, Lorincz AT: Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer 2015; 136:E638-E645.
11. Vasiljević N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Moller H, Yu Y, Lu YJ, Cuzick J, Foster CS, Lorincz AT: 2013. Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 35-40.
12. Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M: DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as a novel epigenetic biomarker. Carcinogenesis 2013; 34: 102-108.
13. Williams M, Werner B, Barnes CP, Graham TG, Sottoriva A: Identification of neutral tumor evolution across cancer types. Nat Genet 2016; 48: 238-244.
14. Martinez P, Timmer MR, Lau CT, Calpe S, Sancho-Serra MDC, Straub D, Baker AM, Meijer SL, ten Kate FJW, Mallant-Hent RC, Naber AHJ, van Oijen AHAM, Baak LC, Scholten P, Bohmer CJM, Fockens P, Bergman JGHM, Maley CC, Graham TA, Krishnadath KK: Dynamic clonal equilibrium and predetermined cancer risk in Barrett's esophagus. Nat Commun 2016; 7: 12158.
15. International Agency for Research on Cancer, World Health Organization: GLOBOCAN 2012. http://globocan.iarc.fr.
16. Lazcano-Ponce E, Lorincz AT, Cruz-Valdes A, Salmeron J, Uribe P, Velasco-Mondragón E, Hernandez Nevarez P, Diaz Acosta R, Hernández-Avila M: Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 378: 1868-1873.
17. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, Meijer CJLM, Sankaranarayanan R, Snijders PJF, Szarewski A: New technologies and procedures for cervical cancer screening. Vaccine 2012; 30S:F107-F116.
18. Lorincz AT, Castanon A, Wey Lim AW, Sasieni P: New strategies for papillomavirusbased cervical screening. Womens Health 2013; 9: 443-452.
19. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-532.
20. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal pap smears: a meta analysis of the accuracy to detect high-grade intraeipthelial neoplasia. J Natl Cancer Inst 2004; 96: 280-293.
21. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
22. Dillner J, Reboli M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337:a1754.
23. Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, DeMarco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G: Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-176.
24. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ: Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79: 328-337.
25. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
26. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL: Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136: 189-197.
27. Hesselink AT, Heideman DAM, Steenbergen RDM, Gok M, van Kemenade FJ, Wilting SM, Berkhof J, Meijer CJLM, Snijders PJF: Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage highrisk HPV-positive women for colposcopy. Int J Cancer 2014; 135: 880-886.
28. Verhoef VMJ, Heideman DAM, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, Bekkers RLM, Massuger FAG, Steenbergen RDM, Snijders PJF, Berkhof, J, Meijer CJLM: Methylation marker analysis of HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol 2014; 135: 58-63.
29. Lagos M, Van De Wyngard V, Poggi H, Cook P, Viviani P, Barriga MI, Pruyas M, Ferreccio C: HPV16/18 genotyping for the triage of HPV positive women in primary screening in Chile. Infect Agent Cancer 2015; 10: 43.
30. Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A: A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol 2014; 59: 161-166.
31. Laird PW: Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010; 11: 191-203.
32. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU: Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: considerations for use as biomarkers of the progression of cervical neoplasia. Virology 2014; 448: 314-321.
33. Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J, Lorincz AT: A DNA methylation classifier of cervical pre-cancer based on human papillomavirus and human genes. Int J Cancer 2014; 135: 1425-1432.
34. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, Lorincz AT: DNA methylation assay for HPV33 contributes independent triage information to HPV16, HPV18, HPV31, and EPB41L3 for detecting cervical pre-cancer. Cancer Biomark 2015; 15: 669-675.
35. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J, Vasiljević N: Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer 2016; 138: 2745-2751.
36. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, Gajda M, Hoyer H, Runnenbaum IB, Durst M: A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One 2014; 9:e91905.
37. Burnett ST, Sleeman J: Uneven distribution of methylation sites within the human papillomavirus 1a genome: possible relevance to viral gene expression. Nucleic Acids Res 1984; 12: 8847-8860.
38. Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, LaMere B, Clarke M, Lorincz AT, Castle PE, Schiffman M, Burk RD: Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104: 1738-1749.
39. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz A: Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 2014; 132: 709-714.
40. Hesselink AT, Heideman DAM, Steenbergen RDM, Coupe VMH, Overmeer RM, Rijkaart D, Berkhof J, Meijer CJLM, Snijders PJF: Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-2465.
41. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, Bekkers RL, Steenbergen RD, Massuger LF, Melchers WJ, Bulten J, Overbeek LI, Berkhof J, Snijders PJ, Meijer CJ: Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014; 15: 315-322.
42. Eijsink JJH, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, van der Zee AGJ, Wisman GBA: A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012; 130: 1861-1869.
43. Lai HC, Ou YC, Chen TC, Huang HJ, Cheng YM, Chen CH, Chu TY, Hsu ST, Liu CB, Hung YC, Wen KC, Yu MH, Wang K: PAX1/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study. Cancer Med 2014; 3: 1062-1074.
44. Wilhelm T: Phenotype prediction based on genome-wide DNA methylation data. BMC Bioinformatics 2014; 15: 193.
45. Pun PB, Liao YP, Su PH, Wang HC, Chen YC, Hsu YW, Huang RL, Chang CC, Lai HC: Triage of high-risk human papillomavirus positive women by methylated POU4F3. Clin Epigenetics 2015; 7: 85.
46. Chang CC, Ou YC, Wang KL, Chang TC, Cheng YM, Chen CH, Chu TY, Hsu ST, Liou WS, Chang YY, Wu HH, Chen TH, Lai HC: Triage of atypical glandular cell by SOX1 and POU4F3 methylation: a Taiwanese Gynecologic Oncology Group (TGOG) study. PLoS One 2015; 10:e0128705.
47. Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, Schuuring E, Wisman GBA: Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics 2016; 8: 29.
48. De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM: Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage-and brushbased self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 2016; 141: 341-347.
49. Luttmer R, De Strooper LMA, Dijkstra MG, Berkhof J, Snijders PJF, Steenbergen RDM, van Kemenade FJ, Rozendaal L, Helmerhorst TJM, Verheijn RHM, ter Harmsel WA, van Baal WM, Graziosi PGCM, Quint WGV, Spruijt JWM, van Dijken DKE, Heideman DAM, Meijer CJLM: FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Canc 2016; 115: 579-582.
50. De Vuyst H, Franceschi S, Plummer M, Mugo NR, Sakr SR, Meijer CJLM, Heideman DAM, Tenet V, Snijders PJF, Hesselink AT, Chung MH: Methylation levels of CADM1, MAL and MIR124-2 in cervical scrapes for triage of HIV-infected, high-risk HPV-positive women in Kenya. J Acquir Immune Defic Syndr 2015; 70: 311-318.
51. Xu J, Xu L, Yang B, Wang L, Lin X, Tu H: Assessing methylation status of PAX1 in cervical scrapings as a novel diagnostic and predictive biomarker was closely related to screen cervical cancer. Int J Clin Exp Pathol 2015; 8: 1674-1681.
52. Wang KH, Lin CJ, Liu CJ, Liu DW, Huang RL, Ding DC, Weng CF, Chu TY: Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV. Cancer Med 2015; 4: 43-55.
53. De Strooper LMA, Hesselink AT, Berkhof J, Meijer CJLM, Snidjers PJF, Steenbergen RDM, Heideman DAM: Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev 2014; 23: 1933-1937.
54. Kan YY, Liou YL, Wang HJ, Chen CY, Sung LC, Chang CF, Liao CI: PAXI methylation as a potential biomarker for cervical cancer screening. Int J Gynecol Cancer 2014; 24: 928-934.
55. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DAM, Massuger LFAG, Verhoef VMJ, Bulten J, Melchers, WJG, van der Zee AGJ, Bekkers RLM, Wisman GBA: DNA methylation analysis in selfsampled brush material as a triage test in hrHPV-positive women. Br J Cancer 2014; 111: 1095-1101.
56. De Strooper LMA, Meijer CJLM, Berkhof J, Hesselink AT, Snijders PFJ, Steenbergen RDM, Heideman DAM: Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res 2014; 7: 1251-1257.
57. De Strooper LMA, van Zummeren M, Steenbergen RDM, Bleeker MCG, Hesselink AT, Wisman GBA, Snijders PJF, Heideman DAM, Meijer CJLM: CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 2014; 67: 1067-1071.